Intelligence Report · ~12 min read

Lupin Pharmaceuticals Intelligence Report

Generated from 1 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Jun 20, 2026

Confidence

Moderate Confidence · 68%

Evidence

6 items

Sources

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Lupin Pharmaceuticals maintains an active intelligence profile across Infectious Disease, Antibiotic. 1 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with low portfolio impact. Evidence coverage stands at 68% across 2 tracked sources. Highest-priority development: FDA AP — VYEPTI (SUPPL). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Lupin Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

regulatory
FDA AP — VYEPTI (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA TA — ANDA219413
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA TA — ANDA220639
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — DOXYCYCLINE HYCLATE (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — DOXYCYCLINE (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 16 with buyer quality 3 (Low Priority). Competitive pressure: Low. Portfolio impact: Low.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

FDA AP — VYEPTI (SUPPL)
Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA TA — ANDA219413
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA TA — ANDA220639
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — DOXYCYCLINE HYCLATE (SUPPL)
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — DOXYCYCLINE (SUPPL)
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

Lupin's Doxycycline ANDA204234 Receives AP Status from FDA
Infectious Disease · Antibiotic

Executive Summary

Key Developments

FDA AP — VYEPTI (SUPPL)

FDA TA — ANDA219413

FDA TA — ANDA220639

FDA AP — DOXYCYCLINE HYCLATE (SUPPL)

FDA AP — DOXYCYCLINE (SUPPL)